The findings presented here, suggesting that loss of the BRCA2wt allele is a late, rather than early, event in progression toward metastatic disease, have clinical relevance supporting adjuvant, and not single-agent, use of PARP inhibitors in treatment of BRCA2 carriers. The gene discussed is BRCA2; the disease is metastatic neoplasm.